Plain-English answer
U.S.-China healthcare comparison is useful when it identifies the actual decision-maker. The United States is fragmented across Medicare, Medicaid, commercial payers, employers, providers, coding systems, FDA, and state rules. China is more state-steered and public-hospital-centered, but local implementation, public insurance rules, household cost sharing, NMPA approval, NHSA reimbursement, and hospital procurement still create separate gates.
When to use this page
Use this FAQ when a question is broad: which system is more public, whether China has universal insurance, whether FDA approval helps in China, why U.S. market entry is hard for Chinese firms, or why China market entry is hard for U.S. firms. The answer usually depends on the gate being discussed: coverage, price, approval, procurement, hospital adoption, patient access, or data use.
Fast orientation
The FAQ is organized around institutional translation: the same words often point to different operating mechanisms in the two systems.
Questions and answers
Does China have universal healthcare?
China has broad basic medical insurance coverage. WHO China reports that basic health insurance covers more than 95 percent of the population. That is not the same as free care or equal access. Reimbursement depends on local rules, insurance category, service type, provider level, deductibles, ceilings, and whether care occurs outside the patient's insured locality.
Is China's healthcare system public?
It is state-steered and public-hospital-centered, but not simply state-run. Public hospitals dominate care volume, public insurance funds are central, and national agencies set reform direction. At the same time, patients pay out of pocket, private hospitals exist, commercial insurance is growing, and local implementation varies substantially.
Why are public hospitals so important in China?
The Commonwealth Fund reports that China had more private than public hospitals in 2023, but public hospitals still provided most outpatient visits and hospitalizations. Public hospitals concentrate specialist authority, teaching, research, procurement demand, and patient trust. That makes them central to market access and reform.
Is FDA approval useful in China?
It can help credibility, especially for global evidence and investor confidence, but it does not replace NMPA registration, local evidence needs, NHSA reimbursement, provincial procurement, hospital formulary or device adoption, or local service support.
Is NMPA approval enough for China market access?
No. NMPA approval addresses regulatory permission for a product. Market access may still require reimbursement, procurement qualification, hospital budget approval, clinical department support, local distribution, after-sales service, and compliance controls.
Why is U.S. market entry hard for Chinese healthcare companies?
FDA status is only one gate. CMS explicitly separates coding, coverage, and payment processes. A company may also need CPT or HCPCS strategy, Medicare or commercial coverage evidence, hospital value analysis, liability planning, data privacy compliance, U.S. service support, and trusted clinical references.
Which system is better?
That is usually the wrong first question. A better question is better for what: rural access, advanced oncology, price control, medical innovation, primary care, drug affordability, digital health, or catastrophic financial protection? Different mechanisms perform differently on each task.
Evidence context
FAQ answers are orientation points. Use the linked source pages for topic-specific evidence before making policy, investment, or market-entry decisions.
- WHO China is useful for financing and insurance coverage context.
- Commonwealth Fund's China profile summarizes hospital, insurance, workforce, and governance structure.
- CMS guidance for medical technology companies explains why U.S. coding, coverage, and payment must be separated.